written on 07.05.2014

Allergan's strong Q1 overshadowed by Valeant buyout questions


Allergan reported some strong first-quarter numbers today, beating analyst estimates for earnings and sales alike. But with a takeover offer hanging over its head, the company didn't get much time–or news space–to brag about the results.

Latest Reports